

2.7.5. Literature References

Tirzepatide (LY3298176)

Lilly Research Laboratories
Eli Lilly and Company
Indianapolis, Indiana, USA

Confidential Information

The information contained in this document is confidential and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries.

Note to Regulatory Authorities: this document may contain protected personal data and/or commercially confidential information exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public release. In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries.

Document ID: VV-CLIN-116181

Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. *Diabetes Obes Metab.* 2016;18(3):203-216. <https://doi.org/10.1111/dom.12591>